<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465059</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-107</org_study_id>
    <nct_id>NCT03465059</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Zanubrutinib (BGB-3111) in Subjects With Varying Degrees of Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and pharmacokinetics of zanubrutinib in
      subjects with impaired liver function in comparison with healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Actual">October 19, 2018</completion_date>
  <primary_completion_date type="Actual">October 19, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of Zanubrutinib (BGB-3111) to evaluate protocol specified PK parameters</measure>
    <time_frame>Days 1, 2 &amp; 3</time_frame>
    <description>Plasma concentration of Zanubrutinib (BGB-3111) to evaluate Area Under the Plasma Concentration-Time Curve (AUC) of Zanubrutinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Zanubrutinib (BGB-3111) to evaluate protocol specified PK parameters</measure>
    <time_frame>Days 1, 2 &amp; 3</time_frame>
    <description>Plasma concentration of Zanubrutinib (BGB-3111) to evaluate Maximum Observed Plasma Concentration (Cmax) of Zanubrutinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Adverse Events (AE)</measure>
    <time_frame>up to Day 17</time_frame>
    <description>Percentage of Participants with Treatment-Emergent Adverse Events (AE)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hepatic Insufficiency &amp; Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal hepatic function will be administered a single oral dose of Zanubrutinib (80 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Zanubrutinib (80 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Zanubrutinib (80 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of Zanubrutinib (80 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>A single oral dose of 80 mg Zanubrutinib will be administered.</description>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female subjects in good health as determined by past medical history,
             physical examination, vital signs, ECG and laboratory tests at screening.

          -  Subjects must have a body mass index (BMI) between 18 and 40 kg/m2 to participate at
             screening.

          -  Female subject must be of non-childbearing potential, i.e. surgically sterile at least
             6 months prior to screening with supportive clinical documentation OR post-menopausal
             must have no regular menstrual bleeding for at least 12 months prior to inclusion.
             Menopause will be confirmed by a plasma FSH level of &gt;40 IU/L

          -  Male subjects must agree to practice 2 highly effective methods of birth control at
             least one method must be barrier technique.

        Additional Inclusion Criteria for Healthy Subjects Only:

          -  In good health as determined by past medical history, physical examination, vital
             signs, ECG, and laboratory tests at screening; subjects without diseases/conditions

          -  Matched with a hepatic impaired patient (mild, moderate or severe, as applicable)
             using the following criteria: sex, age ±10 years and body mass index (BMI)± 10
             kilograms

        Additional Inclusion Criteria for Hepatic Impaired Subjects Only:

          -  History of cirrhosis with supportive documentation (ultrasonography, computed
             tomography scan, liver biopsy, magnetic resonance imaging, clinical laboratory tests
             results or physical signs consistent with a clinical diagnosis of liver cirrhosis.

          -  Child-Pugh Clinical Assessment Score consistent with degree of hepatic impairment.

          -  Blood pressure of 90 to 155 mmHg (systolic) and 50 to 100 mmHg (diastolic).

          -  Otherwise considered healthy in general as determined by physical examination findings
             and laboratory assessments within normal limits.

        Exclusion Criteria:

          -  Subjects with a clinically relevant history or presence of any clinically significant
             disease.

          -  History of drug or alcohol abuse within the 12 months prior to dosing.

          -  A positive human immunodeficiency virus (HIV) Type 1 or 2 test result at screening.

          -  History of blood donation of 500 mL or more of blood within 2 months prior to
             screening

          -  A positive tuberculosis test result.

        Additional Exclusion Criteria for Hepatic Impaired Subjects Only:

          -  Received a liver transplant

          -  Acute or exacerbating hepatitis

          -  Active Stage 3 or 4 hepatic encephalopathy

          -  Previously diagnosed with hepatocellular carcinoma, or a history of cholestatic liver
             disease or biliary sepsis within the past 2 years.

          -  Additional Exclusion Criteria for Healthy Subjects Only: A positive Hepatitis B
             surface antigen (HBsAg) or Hepatitis C test result.

          -  History of any clinically significant chronic and/or active hepatic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Novotny, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ou YC, Preston RA, Marbury TC, Tang Z, Novotny W, Tawashi M, Li TK, Sahasranaman S. A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment. Leuk Lymphoma. 2020 Jun;61(6):1355-1363. doi: 10.1080/10428194.2020.1719097. Epub 2020 Feb 7.</citation>
    <PMID>32031037</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BGB-3111</keyword>
  <keyword>Zanubrutinib</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

